Roche cuts the price of breast cancer drug - (BusinessDay via NewsPoints Desk)

  • Roche has cut the price of its breast cancer drug trastuzumab to state patients in South Africa, BusinessDay reported Tuesday.

  • The drug, which is marketed under the names Herceptin and Herclone, has been made available to a limited number of hospitals, while Roche is in talks with the country's health department regarding wider access.

  • The health department hopes to provide the drug, which was included in the nation's list of essential medicines list in June, to 500 people at year in 14 hospitals.

  • Roche spokeswoman Aadila Fakier, who declined to specify the new price, noted that trastuzumab was previously available in South Africa at a price of about 10 500 South African rands per vial.

  • Meanwhile, Mylan has petitioned South Africa's Medicines Control Council for approval of its trastuzumab biosimilar.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.

Reference Articles